Filing Flows › International Stem Cell (ISCO) › Q4 2024
International Stem Cell (ISCO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
International Stem Cell (ISCO) reported revenue of $2.4M for the fourth quarter 2024 (Q4 2024), +29% from a year earlier and +12% from the quarter before. Operating margin was 2.1%, net earnings $11K (0.4% of revenue).
International Stem Cell, Q4 2024: revenue $2.4M (+30% year over year), operating margin 2.1%, net earnings $11K, operating cash flow −$74K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | +12% | +29% |
| Operating profit | $51K | — | — |
| Net earnings | $11K | — | — |
| Operating cash flow | −$74K | — | — |
What changed
Revenue was $2.4M in Q4 2024, up 29% year over year and up 12% from the previous quarter. Biomedical Market was the largest line at 92% of revenue.
Operating profit was $51K, a 2.1% margin (up 24.5 points year over year). Total costs grew 4% against revenue growth of 29%. The fastest-growing cost line was Research & development (+27%). Net earnings were $11K. The effective tax rate was 0.0%.
Operating cash flow was −$74K. Non-cash charges added back $54K of depreciation and amortization and $100K of share-based compensation. Working capital and other items used $239K. Capital expenditures of $1K exceeded it, leaving free cash flow of −$75K.
Questions
What was International Stem Cell's revenue in the fourth quarter 2024?
International Stem Cell (ISCO) reported revenue of $2.4M for the fourth quarter 2024 (Q4 2024), +29% from a year earlier and +12% from the quarter before.
Was International Stem Cell profitable in the fourth quarter 2024?
Operating profit was $51K (2.1% of revenue) and net earnings $11K.